Multi-Modality Management of Melanoma in the Era of Immunotherapy

Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director, Experimental Therapeutics Cedars Sinai Foundation discusses the Multi-Modality Management of Melanoma in the Era of Immunotherapy

This presentation is a part of the MOASC Oncology Summit Annual Educational Symposium

This presentation was made possible by these companies:

Abbvie Oncology

Amag Pharmaceuticals

AstraZeneca

Bayer Oncology

BeiGene

Clovis Oncology

Coherus BioSciences

Daiichi-Sankyo

Jazz Pharmaceuticals

Merck

Pfizer Oncology

Puma Biotechnology

Takeda Oncology

Tempus

Verastem Oncology

Walgreens